The Chongqing-based institute’s 3D printing research center has finished 93 zero gravity flying tests in France. The printer can produce bigger space parts than the one sent to the International Space Station by NASA late last month and could help China build a space station in 2020 and facilitate its operation and maintenance thereafter.

CAS news release, April 19, 2016

In this non-invasive embryo chromosome screening (NICS), DNA released from cultured embryos is sequenced prior to implantation. In China, more than 70 million women per year have tests on chromosomal abnormalities („assisted reproduction cycle“).

China Bio news release, April 18, 2016

The 3 patients have already survived for up to 3 years and all show reduced need of insulin injections.

CAS news release, April 18, 2016

The centers are planned to serve as a genetic test base for a personalized medicine („precision medicine“). Centers will be in Ningbo, Chengdu, Jining, Ningxia, Hunan and other locations.

China Bio, April 15, 2016

A team of China’s Technology and Engineering Center for Space Utilization has completed 93 parabolic test flights in France leading to at least 22 seconds of microgravity. These flights were facilitated by the German DLR. During the flights, various 3D printing experiments with fiber-reinforced polymers were done using Chinese equipment and processes.

CAS news release, April 14, 2016

According to a statement on April 13, the ministry has established a routine monitoring system aimed at the discovery of illicit cultivation of transgenic vegetables. Three cases concerning transgenic corn seed were discovered in Xinjiang, Gansu and Hainan, the plants grown on 1.000 and 100 acres, respectively, were destroyed and the field owners were punished.

China Bio news release, April 14, 2016

A study at Guangzhou Medical University which used human embryos to make them resistant to HIV infection using CRISPR/CAS genome editing tools has led to discussions in China about strengthened legal supervision of such expeeriments. While the Guangzhou work was in line with China’s current regulations, some researchers saw a need for more precise regulations concerning the targets of such research and the ethics surrounding early human embryos.

China Bio news release, April 14, 2016

The objective of this cooperation is to build a cloud-based platform for the development of a nation-wide genome-based personalized medicine („precision medicine“).

China Bio news release, April 14, 2016

The 400 m2 laboratory will be led by Professor Guoping SHI of Harvard Medical School and focus on applications of regulatory T cell technology, e. g., for the treatment of lupus, organ transplantation and cancer.

China Bio news release, April 14, 2016

The consortium comprises leading antibiotic produceers such as the Tonglian Group and Shenyang’s Chinese Academy of Technology. TIB’s HTS screening platform will be used to arrive at higher yields of the antibiotic of which China is already a major producer

CAS news release, April 12, 2016

The process uses a gently enzymatic treatment of oil seed kernels which results in better quality of the product and low cost – the enzyme cost is cited as 24 Yuan/t of oil seed. The process has been scaled to 30 t/day.

China Bio news release, April 11, 2016

The Challenge Group was founded in 1997 by the Chinese Academy of Agricultural Sciences and has developed a series of over 100 kinds of enzyme products such as high temperature phytase, xylanase and glucanase, distributed to 25 provinces , autonomous regions and exported to Europe, America and Southeast Asia. TIB will contribute by HTS screening and other high-tech developments to such innovative products.

CAS news release, April 11, 2016

Resveratrol, a compound found in red wine, reduces the risk of heart disease. Researchers around MI Mantian have found in mice that resveratrol can remodel the gut microbiota including increasing the Bacteroidetes-to-Firmicutes ratios, significantly inhibiting the growth of Prevotella, and increasing the relative abundance of Bacteroides, Lactobacillus, Bifidobacterium, and Akkermansia. The changed intestinal flora reduced levels of trimethylamine-N-oxide (TMAO), a known contributor to the development of atherosclerosis, by inhibiting production of trimethylamine, its precursor.

CAS news release, April 7, 2016

Developments are under the Ministry of Science and the National Health and Family Planning Commission, but private organisations are also involved. The focus of standardization is on sequencing technology, large-data handling and expert systems for diagnosis, treatment and prevention. In China’s large population, accurate health care is a systematic project, mainly to determine the heterogeneity and subsequent approach to patient groups, thereby directly and indirectly involving related industries. Precision medicine has three levels, the basic level being based on gene sequencing. The medium level mainly involves immunotherapy, strengthening the immune cell functions. The highest level is to edit genes and genomes, e. g. in cancer by transforming cancer cells back to normal cells. in 2012 the number of Chinese cancer patients was 3.065 million, accounting for about one-fifth of global incidence, and cancer deaths were 2.205 million, accounting for about 1/4 of the global number of cancer deaths.

China Bio news release, April 7, 2016

Dr LIU is an expert in immunology and has studied in Birmingham where he also received his postdoctoral training. In 1991, he joined DNAX Schering Ploug Research Center and moved in 2002 to the Texas MD Anderson Cancer Center. He later became VP and Chief Scientist of Baylor Research Institute and Senior VP of MedImmune Inc. The Chinese media celebrate the career of this scientist to become head of R&D of a global Western drug company.

China Bio news release, April 6, 2016

SJ-10 houses 19 experiments including the early stage development of mouse embryos in microgravity. The satellite is scheduled to land in Inner Mongolia at an undisclosed date

CAS news release, April 6, 2016

China’s first stem cell company, founded in 2009, is Guangzhou Saliai Stem Cell Science and Technology Co., and member of the Guangdong Stem Cell and Regenerative Medicine Association. Guangdong Province has invested about 200 million Yuan in this field over the past two years. The alliance is intended to facilitate international exchange in a field of industry which is valued at 100 billion $ by 2020.

CAS news release, April 2, 2016

During the current 5-years’ plan, the city will build a new generation of high-tech zones in this industry segment, relying on over 60 bio-pharmaceutical companies with total annual sales of 22,6 billion Yuan and China’s top marine drug base.

CAS news release, April 1, 2016

The release of IKMobile100 is through the Beijing Branch of Hong Pa Technology Co., Ltd. Effective identification distance is 20-30cm, recognition speed is 1s. The company plans for markets in financial payment, access control, social security and medical care.

CAS news release, March 30, 2016

At China’s Chinese People’s Political Consultative Conference (CPPCC) held on March 24 in Beijing, it was suggested to build science museums, recruit scientists for science education, e. g., for teenagers and rural residents, and use information technology to reach this aim.

CAS news release, March 28, 2016